Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GYRE 
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: GYRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.08% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 684.83M USD | Price to earnings Ratio 377 | 1Y Target Price 18 |
Price to earnings Ratio 377 | 1Y Target Price 18 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 6.11 - 19.00 | Updated Date 10/30/2025 |
52 Weeks Range 6.11 - 19.00 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.08% | Operating Margin (TTM) 8.11% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) 7.84% |
Valuation
Trailing PE 377 | Forward PE 188.68 | Enterprise Value 630045363 | Price to Sales(TTM) 6.7 |
Enterprise Value 630045363 | Price to Sales(TTM) 6.7 | ||
Enterprise Value to Revenue 6.17 | Enterprise Value to EBITDA 54.97 | Shares Outstanding 90826777 | Shares Floating 20459640 |
Shares Outstanding 90826777 | Shares Floating 20459640 | ||
Percent Insiders 87.16 | Percent Institutions 3.78 |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics, Inc. (GYRE) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for unmet medical needs. The company has undergone several transformations and pivots in its history.
Core Business Areas
- Drug Development: Gyre focuses on the development of novel therapeutic candidates. The product pipeline details can vary, and currently the company has a strong focus on innovative drugs for severe disease.
- Commercialization: While in development stage, Gyre Therapeutics aim to commercialize successfully developed drugs in US markets.
Leadership and Structure
Details on the current leadership team and organizational structure are variable depending on company milestones. Investors should refer to the company website for the current team.
Top Products and Market Share
Key Offerings
- F351: F351 is Gyre's leading therapeutic candidate, targeting cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Market share data is pending FDA approval. Competitors include established therapies, potential future competitors from other pharmaceutical firms, and generic options for symptom management.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and a complex competitive landscape.
Positioning
Gyre Therapeutics aims to carve out a niche in the treatment of liver diseases with its novel therapeutic candidates. Its competitive advantages depend on successful clinical trials and regulatory approval.
Total Addressable Market (TAM)
The total addressable market for cholestatic liver diseases is substantial, estimated to be in the billions of dollars globally. Gyre's position in this TAM is currently dependent on the clinical success and commercialization of F351.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Experienced management team
- Strong IP portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
Opportunities
- FDA approval of F351
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ICPTH
- GNFT
- NKSH
Competitive Landscape
Gyre Therapeutics competes with established pharmaceutical companies and emerging biotech firms in the liver disease space. It's dependent on F351.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by preclinical and early clinical trial progress.
Future Projections: Future growth is contingent on the successful development and commercialization of F351.
Recent Initiatives: Recent initiatives include ongoing clinical trials for F351.
Summary
Gyre Therapeutics Inc. is a development-stage biopharmaceutical company with a focus on liver diseases. Its success hinges on the clinical and regulatory progress of its lead therapeutic candidate, F351. The company faces significant challenges, including limited financial resources and competition from established players. Successful commercialization of F351 will be necessary to establish a strong market position. Financial performance is largely dependent on R&D and clinical trial outcomes.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-Party Financial Analysis
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data may be estimated and subject to change. All data is preliminary and subject to revision.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | Interim CEO & Executive Chair Mr. Ping Zhang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.